Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 9040 results

  1. Iptacopan for treating primary IgA nephropathy [ID6640]

    In development Reference number: GID-TA11844 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  3. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    In development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    Discontinued Reference number: GID-TA11163

    Technology appraisal guidance
    Discontinued

  5. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148).

    Withdrawn guidance

  6. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).

    Withdrawn guidance

  7. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    In development Reference number: GID-TA11137 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    In development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    In development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  11. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

    Medical technologies guidance
    In development

  12. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    Discontinued Reference number: GID-TA11007

    Technology appraisal guidance
    Discontinued

  13. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development